CAMERON DENNIS: Open Payments
NPI 1922756196 · LAUREL, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,905 in 94 payments from 34 companies in 2025. Trend: 2023 $1,775 · 2024 $2,174 · 2025 $1,905
Food & beverage: $1,905
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 11 | $234 |
| Novartis Pharmaceuticals Corporation | 8 | $169 |
| Daiichi Sankyo Inc. | 5 | $120 |
| Incyte Corporation | 5 | $105 |
| Astellas Pharma US Inc | 5 | $105 |
| Janssen Biotech, Inc. | 5 | $92 |
| Exelixis Inc. | 3 | $79 |
| PFIZER INC. | 4 | $76 |
| Gilead Sciences, Inc. | 3 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $73 |
Products named: KEYTRUDA, ENHERTU, REBLOZYL, CABOMETYX, Vyloy, Trodelvy, KISQALI, RYBREVANT.
Industry payments across MS — which companies pay providers there.
